RIV

Rivus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering a new class of medicines called Controlled Metabolic Accelerators (CMAs) to address metabolic and cardiometabolic diseases. The company's lead asset, HU6, is a once-daily oral small molecule that promotes weight loss by increasing resting energy expenditure through mitochondrial uncoupling. Unlike incretin-based therapies, HU6 specifically targets fat reduction while sparing lean muscle mass, offering a potentially differentiated approach for treating obesity. The company is also evaluating HU6 in clinical trials for heart failure with preserved ejection fraction (HFpEF) and metabolic dysfunction-associated steatotic liver disease (MASLD). Rivus aims to provide a foundational therapy for patients who require significant weight loss or metabolic improvement without the muscle loss often associated with GLP-1 receptor agonists.